The Shareholders Foundation announces that an investigation on behalf of investors, who purchased shares of MiMedx Group Inc (NASDAQ:MDXG), is ongoing over potential breaches of fiduciary duties by certain officers and directors at MiMedx Group.
Investors who purchased shares of MiMedx Group Inc (NASDAQ:MDXG) and currently hold any of those NASDAQ:MDXG shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain MiMedx Group officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On September 4, 2013, MiMedx Group Inc confirmed that it is in receipt of an “Untitled Letter” from the Food and Drug Administration (“FDA”) in connection with MiMNedx Group Inc’s Amnion / Chorion Injectable products’ eligibility for marketing solely under Section 361 of the Public Health Service Act.
MiMedx Group Inc reported that its annual Total Revenue rose from $0.79 million in 2010 to $59.18 million in 2013 and that its respective Net Loss declined from $11.42 million to $4.11 million. Shares of MiMedx Group Inc (NASDAQ:MDXG) grew from $0.78 per share in early 2010 to as high as $8.74 per share in late 2013.
On September 26, 2014, NASDAQ:MDXG shares closed at $7.21 per share.
Those who purchased shares of MiMedx Group Inc (NASDAQ:MDXG) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego